Orlance
Orlance is a biotech company focused on developing needle-free, powdered nucleic acid vaccines (DNA and RNA) using its innovative MACH-1 platform. The company aims to improve global health access by providing stable, easy-to-deploy vaccines that do not require cold chain logistics, with applications in infectious diseases and cancer immunotherapy.
Industries
Nr. of Employees
small (1-50)
Products
Needle-free microparticle epidermal vaccine delivery system
A device and powdered vaccine platform that uses pressurized gas to deliver DNA- or RNA-coated microparticles into the epidermis for dose-sparing, room-temperature-stable vaccination without needles.
ORLANCE MACH-1
An epidermal vaccine delivery platform designed for delivering powdered, needle-free, low-dose, and thermostable nucleic acid vaccines (DNA and/or RNA) without cold chain requirements.
Needle-free microparticle epidermal vaccine delivery system
A device and powdered vaccine platform that uses pressurized gas to deliver DNA- or RNA-coated microparticles into the epidermis for dose-sparing, room-temperature-stable vaccination without needles.
ORLANCE MACH-1
An epidermal vaccine delivery platform designed for delivering powdered, needle-free, low-dose, and thermostable nucleic acid vaccines (DNA and/or RNA) without cold chain requirements.
Services
Collaborative development, co-development arrangements, and funding partnerships to advance nucleic acid vaccine and immunotherapy programs into clinical development.
Optimization of DNA/RNA formulations for microparticle delivery, stability testing, and comparative immunogenicity studies versus alternative delivery modalities.
Preclinical validation, formulation and adjuvant incorporation, and activities to prepare vaccine candidates for Phase 1 clinical trials.
Collaborative development, co-development arrangements, and funding partnerships to advance nucleic acid vaccine and immunotherapy programs into clinical development.
Optimization of DNA/RNA formulations for microparticle delivery, stability testing, and comparative immunogenicity studies versus alternative delivery modalities.
Preclinical validation, formulation and adjuvant incorporation, and activities to prepare vaccine candidates for Phase 1 clinical trials.
Expertise Areas
- Needle-free epidermal vaccine delivery
- Powdered nucleic acid vaccine formulation and stabilization
- Preclinical vaccine and immunotherapy development
- Formulation optimization for microparticle delivery
Key Technologies
- Microparticle gene-gun (pressurized gas) epidermal delivery
- Powdered nucleic acid vaccine formulations
- Microparticle (metal) nucleic acid coating
- DNA vaccines
News & Updates
Orlance received a NIH SBIR grant to develop an enhanced seasonal influenza vaccine using its MACH-1 platform, aiming to provide better protection against mismatched circulating strains and to stimulate diverse immune responses.
Orlance received a NIH SBIR grant to develop and optimize RNA vaccine formulations using its MACH-1 platform, which enables stable, needle-free, and room-temperature stable RNA vaccines.
Orlance received a NIH SBIR grant to develop a universal influenza vaccine using its MACH-1 platform, aiming for a low-dose, rapidly produced, and easily distributed vaccine.
Orlance received a NIH SBIR grant to develop DNA and RNA vaccines for melanoma using its MACH-1 platform, targeting tumor-specific immune responses.
Orlance received a NIH SBIR grant to develop a universal influenza vaccine with its MACH-1 platform, focusing on broad antibody and cellular immune responses.
An article discussing Orlance's gene gun technology and its potential to enable a universal flu vaccine.
Orlance received a NIH SBIR grant to develop an enhanced seasonal influenza vaccine using its MACH-1 platform, aiming to provide better protection against mismatched circulating strains and to stimulate diverse immune responses.
Orlance received a NIH SBIR grant to develop and optimize RNA vaccine formulations using its MACH-1 platform, which enables stable, needle-free, and room-temperature stable RNA vaccines.
Orlance received a NIH SBIR grant to develop a universal influenza vaccine using its MACH-1 platform, aiming for a low-dose, rapidly produced, and easily distributed vaccine.
Orlance received a NIH SBIR grant to develop DNA and RNA vaccines for melanoma using its MACH-1 platform, targeting tumor-specific immune responses.
Orlance received a NIH SBIR grant to develop a universal influenza vaccine with its MACH-1 platform, focusing on broad antibody and cellular immune responses.
An article discussing Orlance's gene gun technology and its potential to enable a universal flu vaccine.